B. Riley lowered the firm’s price target on Rigel Pharmaceuticals to $1.25 from $1.75 and keeps a Neutral rating on the shares. The company’s Q3 update was highlighted by growing Tavalisse sales, as Rigel delivered the highest total number of bottles sold in the U.S. during the quarter, the analyst tells investors in a research note. However, revised assumptions for Rezlidhia drove the target drop.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RIGL:
- Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update
- Rigel Pharmaceuticals reports Q3 EPS (3c), consensus (7c)
- Is RIGL a Buy, Before Earnings?
- Cantor Fitzgerald biotech analysts to hold an analyst/industry conference call
- Alpine Immune Sciences appoints Wolfgang Dummer to CMO